Pavlos Msaouel

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (21)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (10)

Bettzy Stephen

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Ruitao Lin

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Peter F Thall

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Andrew Chapple

Assistant Professor

LSU Health Sciences Center

UNITED STATES

View details

Daniele Robesti

Vita-Salute San Raffaele University

ITALY

View details

Cara Haymaker

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Adina Passy

University of North Texas Health Science Center

UNITED STATES

View details

Charles Nguyen

Assistant Clinical Professor

City Of Hope National Medical Center

UNITED STATES

View details

Surena F. Matin

University of Texas at Austin

UNITED STATES

View details

Alberto Martini

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Pavlos Msaouel

Research Interests

Explore related searches

Contact this professor

Articles (21)

Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study

Random Assignment, But Without Comparison: A Missed Opportunity

Bayesian interim analysis and efficiency of phase III randomized trials

Reproducibility of statistically significant phase III oncology trials: An In Silico meta-epidemiological analysis

Precision generalized phase I-II designs

Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials

Surgical approaches following durable responses to immunotherapy

Bad stats: A regular series exploring slip-ups, snafus and salutary lessons from the world of statistics

Differentiating between renal medullary and clear cell renal carcinoma with a machine learning radiomics approach

Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial

The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: Analysis of individual patient data from IMvigor210 and IMvigor211 Trials.

Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma

Novel clinical trial designs with dose optimization to improve long-term outcomes

Müllerian-Type Clear Cell Carcinoma of Donor Origin in a Male Patient with a Kidney Transplant: Ascertained by Molecular Testing

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma

Bayesian treatment screening and selection using subgroup‐specific utilities of response and toxicity

Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas

Renal Cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2

Less is More? First Impressions From COSMIC-313

Risk Model Development and Validation in Clinical Oncology: Lessons Learned

Utility‐based Bayesian personalized treatment selection for advanced breast cancer

Collaborators (10)

Bettzy Stephen

Ruitao Lin

Peter F Thall

Andrew Chapple

Daniele Robesti

Cara Haymaker

Adina Passy

Charles Nguyen

Surena F. Matin

Alberto Martini

Make your next move.